title: Therapeutics for Equine Endocrine Disorders.
abstract: Equine endocrine disease is commonly encountered by equine practitioners. Pituitary pars intermedia dysfunction (PPID) and equine metabolic syndrome (EMS) predominate. The most logical therapeutic approach in PPID uses dopamine agonists; pergolide mesylate is the most common. Bromocryptine and cabergoline are alternative drugs with similar actions. Drugs from other classes have a poor evidence basis, although cyproheptadine and trilostane might be considered. EMS requires management changes as the primary approach; reasonable justification for use of drugs such as levothyroxine and metformin may apply. Therapeutic options exist in rare cases of diabetes mellitus, diabetes insipidus, hyperthyroidism, and critical illness-related corticosteroid insufficiency.
authors.affiliation: Liphook Equine Hospital, Liphook, Hampshire GU30 7JG, UK. Electronic address: andy.durham@theleh.co.uk.
authors.forename: Andy E
authors.initials: AE
authors.lastname: Durham
mesh_terms: D000818:Animals; D018491:Dopamine Agonists / Q000627:therapeutic use; D004700:Endocrine System Diseases / Q000188:drug therapy / Q000662:veterinary*; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D010479:Pergolide / Q000627:therapeutic use
chemical_list: D018491:Dopamine Agonists; D010479:Pergolide
keywords: Diabetes; EMS; Endocrine; Equine; PPID; Therapeutics